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Abstract
Objective: Prospective study to evaluate the feasibility of a preoperative bronchoscopic radioisotope application, followed by
conventional sentinel lymph-node (SLN) identification and to investigate the occurrence and distribution of micrometastases in relation to
SLN activity. Methods: Twenty patients with a mean age of 63 years and proven clinical stage T1-3 N0-1 non-small-cell lung cancer
(NSCLC) were included. A dosage of 80 MBq radiolabeled technetium-99m nanocolloid was endoscopically administrated on intubated
patients in the operation theatre. At thoracotomy, scintigraphic readings of both the primary tumor and hilar and mediastinal lymph-node
stations were obtained with a hand-held gamma-counter. Patients underwent lung resection and mediastinal lymphadenectomy. Radiolabeled
nodes were also examined separately on back-table. SLNs were defined as the hottest nodes or nodes with at least one-tenth of the
radioactivity of the hottest nodes. SLNs pathologic assessment included standard examination using hematoxylin and eosin staining on step
sections and immunohistochemistry (ICH) for cytokeratins. Results: Identification of SLNs was possible in 19/20 (95%) patients after
bronchoscopic radioisotope application. In 7/19 (37%) patients, a unique SLN was identified, whereas in 12/19 (63%) patients, nodes from
two different stations could be classified as SLNs. Metastatic nodal disease was found in 9/19 (47%) patients. ICH revealed micrometastases
in 2/12 (17%) patients, initially classified nodal negative. Pathologic negative SLNs were a predictor for absence of metastatic nodal disease
after mediastinal lymphadenectomy. No complication related to the procedure was observed. Conclusion: Our preliminary results suggest
that preoperative bronchoscopic radioisotope injection for SLN identification is a safe and simple method, improving accuracy of SLN
detection in comparison to intraoperative technique. The absence of metastases in the SLNs seems to predict a negative nodal status
accurately.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Nodal status is admitted as the most significant predictor
of survival for patients with non-small-cell lung cancer
(NSCLC) [1,2]. As a consequence, adequate lymph-node
staging is mandatory. Proper lymph-node staging is also
required in patients with early stage NSCLC, since the
prognostic significance of pathologic N1 seems to be
different between intralobar and hilar involvement and
since occult lymph-node metastases have been seen in up to
20% of the T1 and T2 tumors [3,4]. Positron emission
tomography (PET) was demonstrated to be more sensitive
and specific than a computed tomographic (CT) scan for
mediastinal lymph-node assessment in patients with poten-
tially operable NSCLC with a high negative predictive
value [5]. However, micrometastases and especially micro-
scopic nodal disease might be underestimated by PET due to
its limitations to detect lesions smaller than 5 mm [6].
Improvement in the pathological examination due to the
introduction of immunohistochemical staining lead to the
identification of micrometastases in 15% of the histologi-
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cally node negative NSCLC [7]. Since the 5-year survival
rate (62%) of patients with micrometastases seemed to be
significantly lower than that of patients without micro-
metastases (86%, P ¼ 0:004) in patients with peripheral
lung adenocarcinoma of 2.0 cm or less in diameter, adjuvant
therapy might be helpful in the patients with nodal
micrometastases [4]. In this respect, the sentinel lymph-
node (SLN) technique might increase the accuracy of
surgical lymph-node staging and assess the prognostic
significance of micrometastatic lymph-node involvement in
patients with early stage NSCLC. SLN mapping with blue-
dye technique and with radioisotopic technetium (Tc)-99m
has been shown as a safe way of identifying the first site of
potential nodal metastases in up to 85% of the lung cancer
patients [1,2,7,8]. Micrometastases could be found in about
20–30% of the positive SLN [7]. The investigators used an
intraoperative or a preoperative CT-guided injection
technique for these questions. Using the intraoperative
technique, blue-dye or radioisotope injection was performed
on atelectatic lung and waiting time, until migration of the
substance was achieved, could be long [2]. In this
prospective study, the main objective was to evaluate the
feasibility of a new preoperative bronchoscopic radioiso-
tope application, followed by conventional SLN identifi-
cation technique. Additionally, the occurrence and
distribution of micrometastases in relation to SLN activity
was investigated.
2. Material and methods
2.1. Patients
Twenty patients with proven NSCLC were prospectively
included in this study between January and September 2002.
The cohort consisted of 14 men and six women, with a mean
age of 63.5 years (range 48–82 years). The protocol was
approved by the Ethic Committee and the Review Board for
protocols dealing with human subjects at the University of
Zurich and the patients were enrolled after informed
consent. Conventional staging by means of a history,
physical findings, blood test, bronchoscopy and contrast-
material-enhanced CT scan of the chest and upper abdomen
was performed in all patients. All patients underwent
integrated whole-body PET/CT for mediastinal staging and
to exclude distant metastases. No patient had suspicion of
mediastinal nodal involvement at the preoperative inte-
grated PET/CT. In all patients, the clinical tumor stage was
T1-3 N0-1 and surgical treatment was intended.
2.2. Preoperative endoscopic application of radioisotope
Patients were initially intubated with a single-lumen
endotracheal tube. Then, bronchoscopy with a fiberoptic
endoscope was performed through the endotracheal tube.
When the tumor was bronchoscopically visible, a protected
needle (MAJ 64/65, 21 gauge £ 13 mm, Olympus Optical
Corporation, Japan) was inserted through the endoscope and
the needle-tip was transbronchially inserted at the tumor
margin. When the tumor was not visible endobronchially,
the needle was inserted at the carina of the most distal
pulmonary sub-segment that could be reached endoscopi-
cally in the proximity of the tumor according to its location
on preoperative CT scan. A mean dosage of 80.2 MBq
(2 mCi, range 78.3–82.6 MBq) radiolabeled Tc-99m nano-
colloid in 1 ml was injected. After injection, a double-lumen
tubus was introduced and the patient was positioned for lung
resection. The mean duration of the bronchoscopic pro-
cedure including the transbronchial injection of Tc was
4 min (range 2–12 min).
2.3. Intraoperative identification of the sentinel lymph-
node(s)
After anterolateral thoracotomy, the value of counts per
second of the primary tumor and intrathoracic nodal stations
were taken with a hand-held gamma-probe counter 358
(Navigator system, Tyco Healthcare Switzerland, 8832
Wollerau). Lung resections were performed with formal
mediastinal lymph-node dissection (MLND) according to
the American Thoracic Society (ATS) mapping system [9].
Measurement of radioactivity was repeated in all the lymph-
node stations and in the tumor specimen on back-table. The
nodes which were considered as sentinel nodes consisted of
the hottest nodes and additionally, all the nodes containing
more than one-tenth of the activity of the hottest nodes were
removed.
2.4. Pathologic evaluation
The hottest sentinel nodes were formalin fixed and
paraffin embedded. They were examined on three-step
sections taken at 250 mm using hematoxylin and eosin (HE)
staining. If no metastases were found, additional immuno-
histochemistry (IHC) for cytokeratins was performed on
unstained slides prepared with the step sections. The
additional sentinel nodes with a radioactivity greater than
one-tenth of the hottest nodes were examined with three
additional step sections and IHC. IHC was evaluated as
positive if demonstrating individual cells or cell clusters
consistent with metastastic cells of the respective
carcinoma.
3. Results
Identification of SLNs was possible in 19/20 (95%)
patients after preoperative bronchoscopic injection of Tc-
99m. In one patient, no radioactivity could be measured at
thoracotomy, 1 h after administration of Tc-99m. This
patient suffered from a squamous cell carcinoma localized
in the apical lower-lobe segment and no technical difficulty
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was observed during injection of Tc-99m. The mean-time
interval between endoscopic injection and first measure-
ment of radioactivity with a hand-held gamma-probe was
1.4 h (range 1–3 h). The mean-time interval between
injection of Tc-99m and definitive identification of SLN
on back-table was 3.3 h (range 2–4.5 h). In 7/19 (37%)
patients, a unique sentinel node was identified, whereas in
12/19 (63%), two separate stations could be classified as
sentinel nodes. These two stations corresponded to the
hottest nodes and to the nodes with radioactive counts
$one-tenth of the hottest nodes. The hottest SLN were
localized in a N1-station in 15/19 (79%) patients, including
ATS 10, 11, 12, 13 in three, six, five and one patients,
respectively. Mediastinal N2 localization was subcarinal
(ATS 7) in three patients and in the aorto-pulmonary
window (ATS 5) in one. No adverse effects related to the
procedure were observed.
3.1. Detection of metastases
Metastatic disease was found in 9/19 (47%) of the
patients within the identified SLNs. Metastases was found in
a single SLN in 7/9 (78%) of these patients and
simultaneously in two SLNs in 2/9 patients (22%). In the
seven patients with single nodal metastases, the hottest
sentinel node was involved in 5/7 (71%); in 2/7 (29%),
metastases were localized in a less radioactive sentinel
node, while the most radioactive node was negative for
tumor. In all seven patients with single SLN metastases, the
involved node stations were N1. In two patients, a
multilevel nodal involvement was observed. The hottest
positive SLN was localized in a N1-station, but metastases
were also found in a less radioactive (.one-tenth) N2
station. In 4/19 (21%) of patients, SLN was localized in the
mediastinum (N2), showing a skip-pattern drainage by
radionucleide activity, but no metastases could be found
either by conventional histopathologic evaluation or by
ICH.
In 2/9 (22%) of patients with nodal metastases, the SLN
was negative by conventional histopathologic evaluation.
Micrometastases and clusters of tumor cells were only
identified after serial sectioning of the nodal tissue and ICH
evaluation by cytokeratin antibody staining in these two
patients. Micrometastases were identified in a N1-lymph-
node in both patient, one in the hottest node and one in a less
radioactive (.one-tenth) SLN. These two patients were
upstaged by the SLN procedure with a stage migration from
stage T2N0 IB to stage T2N1 IIB.
3.2. Accuracy of the technique
In the ten patients with no tumor found in the SLN, there
was also no metastatic disease even after extended
mediastinal lymphadenectomy in nine of them. In one of
these patients with negative SLN in position ATS 12, three
metastatic intrapulmonary nodes were observed in position
ATS 13. However, these involved nodes were encased in the
centrally located tumor (squamous cell carcinoma) and
could not be macroscopically separated any more. Thus,
pathologic negative SLNs were a predictor for absence of
metastatic nodal disease after MLND in this series.
In nine patients, metastatic disease in the SLN was the
only site even after MLND. The hottest SLN was the only
positive node in 6/9 of these patients. In two patients with
tumor positive hottest N1 SLN, metastatic disease was also
found in a mediastinal N2 lymph-node station. However,
these two N2 lymph-nodes had a radioactivity $one-tenth
of the hottest node and could be considered as separate
sentinel nodes.
4. Discussion
4.1. Preoperative bronchoscopic technique
The bronchoscopic injection of the radionucleide
allowed a SLN identification in 95% of patients. Preopera-
tive CT-guided injection of Tc-99m in patients with NSCLC
for identification of SLN was already shown as a reliable
method with a SLN localization in 87% of the patients [8].
These results seem to be superior to the intraoperative
technique where a sentinel node could be found in 47–82%
of patients [1,2]. It may be due to a more physiological way
of injecting Tc-99m on ventilated lungs and to the fact that
the migration of the radionucleide was not affected during
preparation of the structures to be resected as with the
intraoperative technique. The bronchoscopic technique
might provide an advantage, being less invasive for the
patient than the transthoracic approach and revealing no
complications in our experience. Contrary to previous
reports [2], we did not observe failure of radionucleide
migration in large tumors with central necrosis.
4.2. Definition of SLN
In a previous report dealing with melanoma, a less
radioactive node was found to be positive for metastatic
disease in 13%, despite the most radioactive node being
negative [10,11]. Therefore, the authors recommended to
consider as SLNs, not only the hottest nodes but also the
nodes containing at least one-tenth or more of the ex vivo
count of the hottest sentinel node [10]. In our experience, 2/
13 patients (15%) with negative hottest SLN showed
metastases in a less radioactive node, which correlates
with the findings in melanoma and breast cancer studies and
supports our choice for definition of SLN [11].
4.3. Accuracy of the bronchoscopic technique
In 9/10 patients, the negative sentinel nodes represented
the final N0 stage after MLND. These results corroborate
the findings of others, using pre- or intraoperative injection
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of the radionucleide [1,12]. In a patient with negative
peribronchial SLN, three intrapulmonary nodes encased by
the tumor were found to be positive. However, we consider
this not a failure since these nodes were adjacent to the
tumor. Therefore, these results suggest that a pathologic
negative SLN reflects a node negative mediastinum
accurately. Furthermore, all nodal metastases were found
in SLNs, either in the hottest nodes, or in less radioactive
SLNs. Radioactive nodes with activity below the threshold
of one-tenth of the hottest were negative in all cases.
However, despite the excellent specificity of the broncho-
scopic technique, these results have to be considered
carefully, due to the small number of patients included in
this study. Therefore, the question if patients with N0 SLNs
might be spared more extensive lymph-node dissection
cannot be clearly answered at this time of investigation. In
order to spare extensive mediastinal lymphadenectomy,
frozen-section examination of the SLNs should be available.
However, frozen-section analysis was demonstrated to be
less sensitive in detecting micrometastatic disease with 54%
of correct identification of a positive SLN in patients with
breast cancer [12–14]. A serial sectioning examination with
HE section per 2–3 mm-thick block of lymph-node and
routine ICH seem to remain the golden standard to find
micrometastases [15].
4.4. Micrometastases
The presence of micrometastatic disease in lymph-nodes
might be of high prognostic relevance, since previous
reports for colo-rectal carcinoma and NSCLC mentioned
survival curves significantly worse [16,17]. The patients
with micrometastatic disease, only found in the SLN in our
series, represented 17% (2/12) of those initially classified
nodal negative by standard histologic examination and 11%
of the 19 patients with identified SLN. Thus, in nearly 1/10
patients, staging was directly affected, which confirmed the
results of Liptay et al. who found micrometastases in seven
of 91 patients with NSCLC [7]. It has been shown that
allowing the pathologists to focus on either a single lymph-
node or relatively few nodes improves their results in
finding micrometastases [18].
In conclusion, our results suggest that SLN mapping by
use of a preoperative bronchoscopic radioisotope technique
was easy to perform and safe. The diagnostic yield in the
identification of SLN was greater than by the intraoperative
technique. Furthermore, SLN analysis seems to predict a
pathologic N0 staging status accurately when no metastases
were present in the sentinel node. It allows the pathologist to
apply more sensitive but time-consuming techniques
selectively to assess occult lymphatic metastases. In this
respect, SLN technique might refine the nodal staging and
allow us to gain better insight into the biologic behavior of
subgroups of NSCLC which may have an impact on
adjuvant therapies in the future.
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